Part of RI Europe, this event will address the following questions:
The economic and social damage from Covid-19 pales in comparison to the potential harm from mass antimicrobial resistance (AMR). Are investors sleeping on this issue?
What tools and methodologies can investors use to gauge the risks from AMR?
What should be the practical role of investors in addressing AMR?
What are the challenges of engaging with companies on systemic, as opposed to idiosyncratic, risk?
Speakers include:
Emma Berntman, Senior Engagement Specialist, FAIRR Initiative
Sara E. Murphy, Chief Strategy Officer, The Shareholder Commons
Suzi van Es, Investor Engagement Manager, Access to Medicine Foundation
The session will be moderated by Georgia Stewart, CEO, tumelo.
Key Information
| Date: | 14 June 2023 |
| Time: | 11:15 - 12:00 BST (UTC+1) |
| Location: | London, UK |
| Address: | 133 Houndsditch, London |